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INTRODUCTION
Cyclooxygenases (COXs) are the key enzymes in the con-
version of arachidonic acid to prostaglandins. There are two
COX isoforms-COX-1 and COX-2. COX-1 is constitutively
expressed in most tissues and produces prostaglandins for
homeostatic functions (1, 2). COX-2 is highly inducible at
inflammation sites and is associated with various human tu-
mors such as colonic carcinoma (3), gastric carcinoma (4),
prostate carcinoma (5), malignant melanoma (6), or high-
grade gliomas (7). COX-2 expression in tumor cell lines is
also upregulated during increased proliferation (8), inhibi-
tion of apoptosis (9), and neoangiogenesis (10). Recent stud-
ies indicate that COX-2 is overexpressed in several thyroid
carcinomas, particularly papillary carcinoma (11-14). 
Nitric oxide is produced from L-arginine by nitric oxide
synthase (NOS). NOS has one inducible isoform, iNOS, and
two constitutively expressed isoforms; endothelial NOS and
neuronal NOS (15). Among all the three NOS isoforms, iNOS
synthesizes the largest amount of nitric oxide released by cells
in response to cytokines or other agents (16). The overexpres-
sion of iNOS has been demonstrated in chronic inflamma-
tory diseases as well as human tumors, including tumors of
the breast, ovary, stomach, head and neck, and central ner-
vous system (17-21). It has been reported that iNOS plays
an important role in tumorigenesis as a mediator of carcino-
genic nitrosamine formation, DNA damage, neovasculariza-
tion (22), and apoptosis (23). A few studies have demonstrat-
ed that iNOS is overexpressed in several benign and malig-
nant thyroid lesions (24, 25).
The aim of the present study was to examine the differences
in the immunohistochemical expressions of the COX-2 and
iNOS proteins in thyroid neoplasms. Further, we analyzed
several clinicopathological findings, patient age, tumor size,
thyroid capsular invasion, and lymph node metastasis, in pap-
illary carcinoma cases. 
MATERIALS AND METHODS
Tissue specimens 
Samples were selected from 154 patients at the Department
of Pathology, Eulji University Hospital (Daejeon, Korea), and
Chungnam National University Hospital (Daejeon, Korea)
between 1994 and 2003. The diagnoses included papillary
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Cyclooxygenase-2 and Inducible Nitric Oxide Synthase Expression in
Thyroid Neoplasms and Their Clinicopathological Correlation
To evaluate the expressions of cyclooxygenase-2 (COX-2) and inducible nitric oxide
synthase (iNOS) in thyroid neoplasms in a Korean population, we studied a total
of 154 cases: papillary carcinoma of classical type (PTC), 86; follicular adenoma
(FA), 21; follicular carcinoma (FC), 35; medullary carcinoma (MC), 3; undifferenti-
ated carcinoma (UC), 5; and Hurthle cell neoplasm (HN), 4. Using immunohisto-
chemical staining, COX-2 expression was detected in 62 (72.1%) PTC specimens,
5 (23.8%) FA specimens, 10 (28.6%) FC specimens, 0 (0.0%) MC specimens, 1
(20.0%) UC specimen, and 3 (75%) HN specimens. iNOS expression was detect-
ed in 66 (76.7%) PTC specimens, 4 (19.0%) FA specimens, 13 (37.1%) FC speci-
mens, 0 (0.0%) MC specimens, 3 (60.0%) UC specimens, and 4 (100%) HN speci-
mens. The results showed that COX-2 and iNOS were frequently expressed in the
PTC and HN specimens, and iNOS was more frequently overexpressed in the FC
specimens than in the FA specimens. In PTC, COX-2 and iNOS were significantly
overexpressed in patients over 45 yr of age (p=0.029, p=0.041), and iNOS expres-
sion was increased in patients with a large primary tumor (p=0.028). These results
suggest that the upregulation of COX-2 and iNOS may contribute to the tumor pro-
gression of thyroid gland, particularly in PTC and HN, and iNOS may play an adju-
vant role during the tumor progression of FC.
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carcinoma with classical type (PTC) (n=86), follicular ade-
noma (FA) (n=21), follicular carcinoma (FC) (n=35), medu-
llary carcinoma (MC) (n=3), undifferentiated carcinoma (UC)
(n=5), and Hurthle cell neoplasm (HN) (Hurthle cell ade-
noma, n=2; Hurthle cell carcinoma, n=2). Each specimen
was subjected to histological evaluation to confirm the diag-
nosis, while the relevant clinicopathological information was
retrospectively abstracted from patient records. The histopatho-
logical slides were reviewed by three pathologists.
Immunohistochemistry 
The specimens were formalin-fixed and paraffin-embedded
blocks. The tissue blocks were freshly cut into 3  m thick
sections onto glass slides. Tissue sections were then deparaf-
finized in xylene and rehydrated through graded alcohol and
deionized water. Afterwards the sections were heated in a mic-
rowave oven in 10 mM citrate buffer (pH 6.0) for 15 min at
100℃ for antigen unmasking. Endogenous peroxidase activi-
ty of the tissues was inactivated by 10 min incubation in 3%
hydrogen peroxide. To block non-specific binding sites, the
slides were then treated with 5% goat serum for 15 min at
room temperature. The sections were incubated for one hour
at room temperature with primary antibody to either COX-
2 mouse antihuman monoclonal antibody at a dilution of
1:100 (Mouse anti-COX-2, Clone: COX 229; Zymed labo-
ratories Inc., South San Francisco, CA, U.S.A.) or with iNOS
epitope specific rabbit antibody at a dilution of 1:100 (Nitric
oxide synthase, inducible: RB-9242-P; Lab vision, Fremont,
CA, U.S.A.). After incubation with the primary antibody,
the sections were processed using standard avidin-biotin im-
munohistochemistry, according to the manufacturer’s recom-
mendations (Vectastain ABC Elite kit; Vector Laboratories,
Burlingame, CA, U.S.A.). Negative controls for the specifici-
ty of anti-COX-2 or anti-iNOS antibody were used by omit-
ting the primary antibody, and these were prepared using
mouse and rabbit immunoglobulins instead of using each
primary antibody individually. Thirty paraffin blocks of nor-
mal thyroid tissue were used as negative controls.
The intensity of the staining was scored 0-3 (absent, mild,
moderate, strong) (Fig. 1, 2) and the area of positivity was
estimated as the percentage of the total area of the tumor
(<10%, 10-50%, and >50%). The final score was a combi-
nation of these two variables and was calculated as follows:
score 0, negative staining or intensity 1+area <10%; score
1, intensity 1+area between 10% and 100% or intensity 2-
Fig. 1. Immunohistochemical staining demonstrates the intensity of COX-2 expression in the cytoplasm of follicular carcinoma cases. (A)
score 0; (B) score 1; (C) score 2; (D) score 3 (×400).
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3+area <10%; score 2, intensity 2+area >50% or intensity
3+area between 10% and 50%; score 3, intensity 3+area
>50%. A final score of 1-3 was defined as positive immunore-
activity. The scoring was performed independently and in a
blinded manner by three pathologists who had no knowledge
of the clinical data. Discrepant scoring was determined by
consensus. 
Statistical analysis
The results were analyzed using one-way ANOVA and
chi-square tests. Statistical package for the social sciences
(SPSS 12.0) was employed. A p value <0.05 was regarded as
statistically significant.
RESULT
Cytoplasmic COX-2 expression (final scores 1-3) was de-
tected in 62 (72.1%) PTC specimens, 5 (23.8%) FA speci-
mens, 10 (28.6%) FC specimens, 0 (0.0%) MC specimen, 1
(20.0%) UC specimen, and 3 (75%) HN specimens. Cyto-
plasmic iNOS expression (final scores 1-3) was detected in
Fig. 2. Immunohistochemical staining demonstrates the intensity of iNOS expression in the cytoplasm of papillary carcinoma cases. (A)








PC 24 25 18 19 86 1.37 0.000
(27.9%) (29.1%) (20.9%) (22.1%)
FA 16 2 2 1 21 0.43
(76.2%) (9.5%) (9.5%) (4.8%)
FC 25 5 3 2 35 0.49
(71.4%) (14.3%) (8.6%) (5.7%)
MC 3 0 0 0 3 0.00
(100%) (0.0%) (0.0%) (0.0%)
UC 4 0 0 1 5 0.60
(80.0%) (0.0%) (0.0%) (20.0%)
HN 1 1 1 1 4 1.50
(25.0%) (25.0%) (25.0%) (25.0%)
Total 73 33 24 24 154 0.99
(47.4%) (21.4%) (15.6%) (15.6%)
Table 1. COX-2 protein staining in thyroid tumors by immuno-
histochemistry
*Statistical analysis was performed by one-way ANOVA.
PC, Papillary carcinoma of classical type; FA, Follicular adenoma; FC,
Follicular carcinoma; MC, Medullary carcinoma; UC, Undifferentiated
carcinoma; HN, Hurthle cell neoplasm.COX-2 and iNOS Expression in Thyroid Neoplasms 1067
66 (76.7%) PTC specimens, 4 (19.0%) FA specimens, 13
(37.1%) FC specimens, 0 (0.0%) MC specimen, 3 (60.0%)
UC specimens, and 4 (100%) HN specimens. The COX-2
and iNOS proteins were frequently expressed in the PTC and
HN specimens. The mean of the COX-2 final scores was 1.37
in the PTC, 0.43 in the FA, 0.49 in the FC, 0.00 in the MC,
0.60 in the UC, and 1.50 in the HN specimens (Table 1). The
mean of the iNOS final scores was 1.73 in the PTC, 0.19 in
the FA, 0.74 in the FC, 0.00 in the MC, 0.80 in the UC, and
1.75 in the HN specimens. The mean value of the iNOS final
scores in the FC specimens was greater than that in the FA
specimens (Table 2). In the normal thyroid tissue, each final
score with regard to COX-2 and iNOS expressions was zero.
Significant positive correlations were detected between COX-
2 and iNOS expressions (Table 3). In PTCs, COX-2 and iNOS
expressions increased in the patients over 45 yr of age, and
high iNOS expression correlated with the primary tumor
size. However, COX-2 and iNOS expressions have not been
shown to be associated lymph node metastasis at operation
(Table 4, 5).
DISCUSSION
In this study, the final immunoreactive scores of COX-2
and iNOS expressions were significantly high in the PTC and
HN specimens. In contrast, the FA, FC, MC, and UC speci-






PC 20 13 23 30 86 1.73 0.000
(23.3%) (15.1%) (26.7%) (34.9%)
FA 17 4 0 0 21 0.19
(81.0%) (19.0%) (0.0%) (0.0%)
FC 22 3 7 3 35 0.74
(62.9%) (8.6%) (20.0%) (8.6%)
MC 3 0 0 0 3 0.00
(100.0%) (0.0%) (0.0%) (0.0%)
UC 2 2 1 0 5 0.80
(40.0%) (40.0%) (20.0%) (0.0%)
HN 0 1 3 0 4 1.75
(0.0%) (25.0%) (75.0%) (0.0%)
Total 64 23 34 33 154 1.23
(41.6%) (14.9%) (22.1%) (21.4%)
Table 2. iNOS protein staining in thyroid tumors by immunohis-
tochemistry
*Statistical analysis was performed by one-way ANOVA.
PC, Papillary carcinoma of classical type; FA, Follicular adenoma; FC,
Follicular carcinoma; MC, Medullary carcinoma; UC, Undifferentiated





0 50 (68.5%) 10 (30.3%) 3 (12.5%) 1 (4.2%) 64 (41.6%)
1 6 (8.2%) 7 (21.2%) 5 (20.8%) 5 (20.8%) 23 (14.9%)
2 13 (17.8%) 11 (33.3%) 6 (25.0%) 4 (16.7%) 34 (22.1%)
3 4 (5.5%) 5 (15.2%) 10 (41.7%) 14 (58.3%) 33 (21.4%)
Total 73 33 24 24 154 
(100.0%) (100.0%) (100.0%) (100.0%) (100.0%)
*p=0.000
Table 3. Correlation between COX-2 and iNOS expression in the
thyroid neoplasms





<45 19 (39.6%) 14 (29.2%) 8 (16.7%) 7 (14.6%) 48 (100%)
≥45 5 (13.2%) 11 (28.9 %) 10 (26.3%) 12 (31.6%) 38 (100%)
p=0.029
Tumor size
T1  7 (25.0%) 8 (28.6%) 7 (25.0%) 6 (21.4%) 28 (100%)
T2  3 (17.6%) 7 (41.2%) 3 (17.6%) 4 (23.5%) 17 (100%)
T3  0 (0%) 1 (100%) 0 (0%) 0 (0%) 1 (100%)
T4  14 (35.0%) 9 (22.5%) 8 (20.0%) 9 (22.5%) 40 (100%)
NS (p=0.770)
LN metastasis
Absent 12 (24.0%) 14 (28.0 %) 12 (24.0%) 12 (24.0%) 50 (100%)
Present 12 (33.3%) 11 (30.6%) 6 (16.7%) 7 (19.4%) 36 (100%)
NS (p=0.697)
Table 4. Relationship between COX-2 final scores by immuno-
histochemical staining and clinicopathological features of papil-
lary carcinoma of classical type
LN, lymph node; NS, not significant; T1, ≤2 cm; T2, >2 cm, ≤4 cm; T3,






<45 15 (31.3%) 8 (16.7%) 13 (27.1%) 12(25.0%) 48 (100%)
≥45 5 (13.2%) 5 (13.2%) 10 (26.3%) 18 (47.4%) 38 (100%)
*p=0.041
Tumor size
T1  7 (25.0%) 2 (7.1%) 13 (46.4%) 6 (21.4%) 28 (100%)
T2  6 (35.3%) 5 (29.4%) 2 (11.8%) 4 (23.5%) 17 (100%)
T3  0 (0%) 0 (0%) 1 (100%) 0 (0%) 1 (100%)
T4  7 (23.3%) 6 (15.1%) 7 (26.7%) 20 (34.9%) 40 (100%)
� p=0.028
LN metastasis
Absent 10 (20.0%) 7 (14.0 %) 16 (32.0%) 17 (34.0%) 50 (100%)
Present 10 (27.8%) 6 (16.7%) 7 (19.4%) 13 (36.1%) 36 (100%)
NS (p=0.593)
Table 5. Relationship between iNOS final scores by immunohis-
tochemical staining and clinicopathological features of papillary
carcinoma of classical type
LN, lymph node; T1, ≤2 cm; T2, >2 cm, ≤4 cm; T3, >4 cm; T4, tumor
of any size extending beyond the thyroid capsule invasion; *, iNOS final
score 0+1 vs. score 2+3; 
� , T1 vs. T2 vs. T3+T4; NS, not significant.1068 K.-H. Kim, S.-H. Kim, S.H. Kim, et al.
overexpression was closely associated with iNOS expression.
The positive correlation between COX-2 and iNOS expres-
sions could be associated with a link between COX-2 and
iNOS pathways because nitric oxide (the product of iNOS
catalysis) is a regulator of COX-2 activity (26) and diverse
prostaglandins (products of COX-2) may affect iNOS expres-
sion (26, 27). It has been observed that COX-2 plays impor-
tant roles in tumor progression as mediators for the develop-
ment of tumor vasculature (10), inhibition of apoptosis (9)
and increasing tumor cell invasiveness (28, 29). Although
the exact signaling pathways of COX-2-promoted tumori-
genesis are yet unknown, several animal studies support a
direct role of COX-2 in tumorigenesis since the genetic dele-
tion of COX-2 suppresses tumor growth and multiplicity
in mice (30). 
Both COX-2 and iNOS overexpressions showed an age-
associated increase in PTCs. Many authors have demonstrat-
ed an age-associated increase in COX-2 activity and prosta-
glandin E2 production in animal models (31), and Siironen
et al. reported that COX-2 expression increased in older pati-
ents with PTC (11). They divided the patients into two groups;
patients less than 35 yr of age and those older than 55 yr of
age. Initially, Ito et al. had reported that COX-2 expression
decreased with age in PTCs (32). They divided patients into
those under and over 54 yr of age. But the Union Internati-
onale Contre le Cancer TNM system classifies all PTC patients
under 45 yr in a low-risk category, independent of tumor size,
extent of tumor, lymph node metastasis, and distant meta-
stasis (33). In our study, we divided PTC patients into two
groups, namely, those under and over 45 yr of age and detect-
ed an age-associated increase in COX-2 and iNOS expressions.
The results were in agreement with the report of Siironen et
al. and demonstrated that the overexpression of COX-2 and
iNOS could correlate with the more aggressive behavior of
PTC.
Similar to the COX-2 expression, we detected iNOS over-
expression in PTC and HN specimens and iNOS expression
was increased in patients with a large primary tumor. The
iNOS overexpression in the PTC specimens is in line with
the previous reports (13, 25). Previous reports suggested that
the nitric oxide released by iNOS might be involved in tumo-
rigenesis as an inhibitor of epithelial cell apoptosis (23) and
neoangiogenesis (34). With regard to the FA and FC speci-
mens, iNOS overexpression was more frequently observed
in the FC specimens than in the FA specimens. Among the
FC specimens, there were 37.1% positive cases, whereas among
the FA specimens, there were only 19.0% positive cases. Al-
though this result is insufficient to arrive at a conclusion, we
suggest that iNOS expression analysis could be helpful in
understanding the tumor progression of FC. 
Overexpression of the COX-2 protein in HN specimen has
been reported previously (35), but the role played by COX-
2 and iNOS in HN is unknown. A previous study has shown
that COX-2 and iNOS are overexpressed in the swollen cyto-
plasm of the follicular cells in chronic lymphocytic thyroidi-
tis (13). The swollen cytoplasm of the follicular cells in chron-
ic lymphocytic thyroiditis and in our HN specimens may
have a mitochondrial dysfunction that is related to COX-2
and iNOS.
We have not demonstrated COX-2 and iNOS expression
in the three cases of MCs. However, Bell et al. reported COX-
2 and iNOS expression in nine cases of MC along with im-
munohistochemical reactivity for COX-1 and COX-2 enzymes
(36). Kim et al. reported that one of two MC cases showed
immunohistochemical overexpression for COX-2 (35), and
Choe et al. reported that all the five MC cases showed immu-
nohistochemical overexpression for iNOS (24). The number
of MC cases that we have reported here was too small for sta-
tistical analysis. The association of COX-2 and iNOS expres-
sions with MC should be further investigated for better under-
standing of MC tumorigenesis.
In conclusion, the present immunohistochemical study has
shown that overexpressions of the COX-2 and iNOS proteins
were more frequently observed in PTC and HN specimens
than other thyroid neoplasms. Further, FCs tended to show
iNOS overexpression more frequently than FAs. The expres-
sions of both COX-2 and iNOS increased in older PTC pati-
ents, and iNOS overexpression was correlated with the pri-
mary tumor size of PTC. These preliminary data suggest that
COX-2 and iNOS expressions could be important molecu-
lar events for the tumor progression of PTC and HN, and
iNOS expression could play a role in the tumor progression
of FC. 
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